INTRODUCTİON {#S1}
============

Chronic graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic cell transplantation (HCT) with significant effects on quality of life, survival and other transplant outcomes. Chronic GVHD occurs in 30 % to 50 % of allogeneic HCT recipients and is often associated with significant late morbidity and mortality.^[@R1]--[@R6]^ Chronic GVHD is an immune-mediated disorder affecting multiple organ systems with heterogenous clinical manifestations. In 2005, the National Institutes of Health (NIH) Consensus Working Group for Diagnosis and Staging of Chronic Graft-versus-Host Disease proposed criteria for diagnosis, subcategorization of acute and chronic GVHD, organ-specific severity scoring, global severity assessment, and indications for systemic treatment.^[@R7]^ Organ- specific severity scoring was based on assessment of the current status of each organ or site without a requirement for knowledge of past manifestations, attribution of abnormalities to chronic GVHD, or belief that the manifestation reflected an active versus a fixed deficit; clinicians simply scored the patient's current condition.

Several prospective studies have reported that organ severity scoring per the 2005 NIH Chronic GVHD Consensus Criteria is a valid and sensitive method for evaluating individual organ involvement and clinical monitoring.^[@R8]--[@R12]^ Individual organ scoring may be combined as an NIH global severity score that showed marked associations with functional, quality of life, and survival outcomes measures.^[@R13]--[@R15]^ Despite these standardized criteria for chronic GVHD organ scoring and global severity, their application in clinical practice raised many questions about guidance to score abnormalities without considering past manifestations, fixed deficits, or whether abnormalities are attributable to chronic GVHD or another cause. Two key practical questions about the 2005 NIH organ scoring consensus criteria are: 1) Should we score symptoms or signs not attributed to chronic GVHD and 2) if yes, how should these organ scores be incorporated into the calculation of global severity. The aim of this prospective cross-sectional study was to describe the confounding factors affecting the 2005 NIH 0--3 organ score and global severity in patients with chronic GVHD.

MATERIALS AND METHODS {#S2}
=====================

Patients {#S3}
--------

All outpatients were prospectively evaluated for GVHD manifestations using a standardized assessment form between January and December 2013 at the Long-Term Follow-Up (LTFU) clinic of Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center. Information from patient visits that met all of the following was used for the analysis: (1) the first visit from each patient during the study period, and (2) diagnosis of chronic GVHD (*classic* or *overlap* subtypes) within 3 years after HCT according to the NIH consensus criteria. Patients gave written informed consent allowing their medical records to be used for research, in accordance with the Declaration of Helsinki, and the Institutional Review Board of the Fred Hutchinson Cancer Research Center approved the study.

GVHD assessment form {#S4}
--------------------

The standard assessment form for organ severity recommended by the 2005 NIH consensus criteria was modified to include two additional questions for each organ site to identify abnormalities that were 1) not attributed to chronic GVHD (yes/no), or 2) attributed to chronic GVHD plus other causes (yes/no).^[@R7]^ If abnormalities not attributed to chronic GVHD were present, causes of the abnormalities were documented by the medical evaluator. For example a patient with elevated liver enzyme tests that may be due to chronic GVHD or medication would be reported under the category of "attributed to chronic GVHD plus other causes." In addition to capturing orgam score plus the attribution of the abnormalities, information about abnormalities in male genitalia and about presence or absence of diagnostic or distinctive features of the mouth in asymptomatic patients were also included in the assessment form.

Statistical analysis {#S5}
--------------------

Descriptive statistics were used to summarize the patient-, transplantation- and GVHD-related characteristics. Continuous variables are presented as median and range, and categorical variables are presented as frequency and percentage. Global severity of chronic GVHD (none, mild, moderate or severe) was calculated from individual organ scores using the NIH consensus criteria algorithm. The higher value was used for final scoring of the lung if discrepancy existed between pulmonary symptom score and pulmonary function test (PFT) scores as recommended in the 2005 NIH consensus criteria for diagnosis and staging of chronic GVHD. Global severity was recalculated with the same algorithm after organ sites solely with abnormalities not attributed to chronic GVHD were scored as zero. In this analysis, the scores of sites that were "attributable to chronic GVHD plus other causes" were not changed.

RESULTS {#S6}
=======

Patient and transplantation characteristics {#S7}
-------------------------------------------

A total of 189 patients with chronic GVHD were evaluated by the LTFU clinical service between January 2013 and December 2013. Patient and transplantation characteristics are shown in [Table 1](#T1){ref-type="table"}. The median patient age at transplantation was 51 (range, 9 to 75) years. Nearly all patients (97%) were adults (greater than 18 years of age). Of the 189 patients, 158 (84%) received mobilized blood cells for transplantation, 110 (58%) had an HLA-matched unrelated donor, and 99 (53%) received myeloablative conditioning. The median interval from transplantation to chronic GVHD diagnosis was 6.9 (range, 2.4 to 37.6) months. The median interval from diagnosis of chronic GVHD to assessment for this study was 8.7 (range, 0 to 39.2) months.

The sites most frequently involved at the time of assessment were skin (59%), mouth (53%), eyes (53%), and lungs (43%) ([Figure 1](#F1){ref-type="fig"}). Sixty out of the 189 patients (32%) presented with diagnostic or distinctive oral features on examination but without any oral symptoms.. One hundred sixty four patients (87%) had available PFT results to allow lung scoring.

Among the 189 patients, 436 (78%) abnormalities were scored and attributed only to chronic GVHD. Eighty (14%) abnormalities were not attributed to chronic GVHD in at least 1 organ, and 41 (7%) of abnormalities were attributed to chronic GVHD plus other causes in at least 1 organ ([Figure 1A](#F1){ref-type="fig"}).

Abnormality and its attribution at individual organ sites {#S8}
---------------------------------------------------------

### Abnormalities not attributed to chronic GVHD {#S9}

Proportions of abnormalities not attributed to GVHD differed according to organ sites, ranging from 2% to 39% ([Figure 1](#F1){ref-type="fig"}). Gastrointestinal tract (39%), lungs (28%), skin (15%), and joints (15%) were the organ sites most frequently affected by abnormalities not attributed to chronic GVHD. Causes of abnormalities not attributed to chronic GVHD are summarized in [Table 2](#T2){ref-type="table"}. Overall, the most frequent causes were abnormalities present prior to transplantation (36%), followed by medication effects (18%), deconditioning (18%), infections (16%), and sequelae from prior GVHD skin involvement (i.e., hyperpigmentation) (9%). Deconditioning refers to tiredness and/or dyspnea only on exertion that is not associated with abnormal pulmonary function tests nor explained by other causes in patients who spent most of the day sitting or lying down (sedentary) who endorse being "out of shape". All manifestations reported as sequelae in the skin were hyperpigmentation. Gastrointestinal abnormalities related to side effects of treatment were diarrhea caused by oral magnesium supplementation and constipation caused by narcotics. Pulmonary abnormalities were caused by deconditioning mostly due to prolonged use of corticosteroids and physical inactivity. These patients had stable mild shortness of breath with normal or stable PFTs.

### Abnormalities attributed to chronic GVHD plus other causes {#S10}

In 2% to 19% of organ scorings symptoms or signs were reported as abnormalities attributed to chronic GVHD plus other causes ([Figure 1](#F1){ref-type="fig"}). For these patients, the liver and gastrointestinal tract were the most prevalent organs (19% and 16%, respectively) and medication side effects, infections, iron overload, and fatty liver were the reported contributing factors for abnormalities present in addition to GVHD.

NIH global severity with or without consideration of confounders {#S11}
----------------------------------------------------------------

Chronic GVHD global severity according to the 2005 NIH algorithm without consideration of attribution was mild in 35 patients (19%), moderate in 109 patients (58%), and severe in 45 patients (24%). After organs and sites with causes not attributed solely to chronic GVHD (n=62) were re-scored as zero, recalculation led to down-grading of the global severity in 18 patients (9.5%) ([Table 3](#T3){ref-type="table"}). Overall severity of chronic GVHD with and without confounders is shown in Figure 2. Four patients with moderate or severe global severity had no chronic GVHD when confounders were considered at the scoring evaluation. Manifestations attributed to scoring in these patients included dry skin (n=2), chronic obstructive pulmonary disease (n=1), irradiation pulmonary fibrosis (n=1), deconditioning as the cause of exertional dyspnea (n=2), infectious conjunctivitis (n=1) and nausea related to dasatinib (n=1). Immunosuppressive treatment was tapered in all patients.

DISCUSSION {#S12}
==========

The NIH consensus criteria provides standardized tools for reporting chronic GVHD (7). While many aspects of the 2005 NIH consensus criteria have been validated by several retrospective and prospective studies,^[@R8]--[@R18]^ daily practice has raised questions about the clinical scoring of organs.^[@R19]^ For instance, the rules for clinically scoring organs do not stipulate whether the abnormality is due to chronic GVHD or other causes. Further, the lack of distinction between active disease (e.g., erythematous rash) and fixed deficits or sequelae (e.g., hyperpigmentation as a consequency from prior rash) provides additional controversy in the implementation of the 2005 NIH consensus criteria.^[@R7]^

In this prospective study, we first examined the incidence and causes of abnormalities not attributed to chronic GVHD in each organ, and then recalculated the global severity by assigning an organ score of zero when abnormalities were not attributed to chronic GVHD. We have demonstrated that overall 14% of abnormal organ scores were attributed only to causes other than GVHD, and this was especially apparent in the lung (28%) and liver (39%). In descending order of importance pre-transplant conditions, medication effects, deconditioning and infection accounted for the majority of abnormal NIH scores unattributed to GVHD. One exception was the skin, where hyperpigmentation, the sequela of active rash, was equally important as a pre-transplant condition in accounting for abnormal skin scores that were not attributed to GVHD. We also observed that 2% to 19% of abnormal organ scores were attributed to chronic GVHD plus other causes. These observations suggest that failure to consider the attribution of organ score abnormalities might result in inappropriately high global severity scores. In our study, near 10% of global severity scores would be lower if certain manifestations were excluded because of these considerations. Four patients with moderate or severe global severity had no chronic GVHD when confounders were considered at the scoring evaluation, suggesting that physicians consider the causes of abnormalities when they make decisions regarding the dose and duration of immunosuppressive treatment.

In a recent survey of controversial areas in the 2005 NIH consensus criteria for diagnosis and scoring of chronic GVHD, investigators showed high agreement on the following two topics. First, signs, symptoms and diagnostic test results clearly not due to chronic GVHD should be scored differently. Second, active disease and fixed deficits should be distinguished in organ severity scoring.^[@R19]^ Our results support this unmet need from the real-world experiences. Notably, a third of patients with chronic GVHD had organ abnormalities from causes other than GVHD. In clinical conditions where physical exam may be insufficient to distinguish active disease and fixed deficits, identification of biomarkers or molecular studies of biopsies may potentially be useful in differentiating these processes.

The NIH chronic GVHD consensus criteria has been recently revised.^[@R20]^ The current consensus incorporates asymptomatic organ manifestations (e.g., asymptomatic oral chronic GVHD). Our results support this change since 32% of HCT recipients presented with asymptomatic diagnostic or distinctive features of mouth involvement.

This study has several limitations. First, this is a single center descriptive study using a relatively small cohort. Correlation with outcomes acording to different scoring algorithms needs to be examined in future studies. Second, most of the patients were adults and the results might not apply to children. Third, although medical records were checked after data entry regarding the organ and site specific abnormalities not attributed to chronic GVHD, the assessment of chronic GVHD and attribution of abnormalities were done by different medical providers who differed in their chronic GVHD expertise. Lastly, quantifying the extent of attribution to chronic GVHD versus clinical confounder remains an open question in the field.

Our results indicate that an unmodified 2005 NIH consensus organ scoring form will collect a substantial proportion of abnormalities attributed to causes other than chronic GVHD. Consideration of "attribution" confounders yields a slight downward shift in the distribution of global severity scores, thereby correcting an overestimation of organ involvement by chronic GVHD. This shift could have consequences for treatment decisions since the NIH consensus criteria advise systemic treatment only for moderate to severe chronic GVHD.^[@R7]^ Our results support the changes recommended by the new 2014 NIH consensus criteria.^[@R20]^
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###### 

Patient and chronic GVHD characteristics

  -------------------------------------------------------------------------------------------------------
  Characteristic                                                                      N = 189
  ----------------------------------------------------------------------------------- -------------------
  **Median patient age at transplantation, y (range)**                                51 (9 -- 75)

  **Patient gender, no. (%)**                                                         

    Male                                                                              127 (67)

    Female                                                                            62 (33)

  **Donor-patient gender combination**[\*](#TFN2){ref-type="table-fn"}**, no. (%)**   

    Female to male                                                                    60 (33)

    Other                                                                             124 (67)

  **Diagnosis, no. (%)**                                                              

    Myeloid malignancy                                                                106 (56)

    Lymphoid malignancy                                                               74 (39)

    Other/non-malignant                                                               9 (5)

  **Conditioning regimen, no. (%)**                                                   

    High intensity without high-dose TBI                                              64 (34)

    High intensity with high-dose TBI                                                 35 (19)

    Reduced intensity                                                                 90 (48)

  **Graft source, no. (%)**                                                           

    Bone marrow                                                                       19 (10)

    Mobilized peripheral blood cells                                                  158 (84)

    Cord blood                                                                        12 (6)

  **HLA matching and donor type, no. (%)**                                            

    HLA-matched related                                                               47 (25)

    HLA-matched unrelated                                                             110 (58)

    HLA-antigen or allele-mismatched                                                  32 (17)

  Months from transplantation to chronic GVHD diagnosis, median\                      6.9 (2.4 -- 37.6)
  (range)                                                                             

  Months from diagnosis of chronic GVHD to assessment, median\                        8.7 (0 -- 39.2)
  (range)                                                                             

  **Involved site, no. (%)**                                                          

    Skin                                                                              111 (59)

    Mouth                                                                             101 (53)

    Eyes                                                                              100 (53)

    Gastrointestinal tract                                                            44 (23)

    Liver                                                                             54 (29)

    Lungs                                                                             82 (43)

    Joint or fascia                                                                   52 (28)

    Genital tract[†](#TFN3){ref-type="table-fn"}                                      14 (7)

  **No. of sites involved, no. (%)**                                                  

    1 or 2                                                                            83 (44)

    3                                                                                 44 (23)

    ≥4                                                                                62 (33)

  **Subcategory of chronic GVHD**                                                     

    Classic                                                                           83 (44)

    Overlap                                                                           106 (56)
  -------------------------------------------------------------------------------------------------------

TBI, total body irradiation; HLA, human leukocyte antigen.

Donor gender was unknown for 5 male patients.

Unknown for 10 patients. Of the 14 patients with genital track abnomalities one was male.

###### 

NIH Organ score abnormalities attributed to causes other than chronic GVHD

  Cause, no. (%)            Skin     Mouth   Eyes     GI tract   Liver   Lungs     Joint    Genital   Total
  ------------------------- -------- ------- -------- ---------- ------- --------- -------- --------- ---------
  Total, no.                17       2       10       17         2       23        8        1         80
  Pretransplant condition   8 (47)   0 (0)   5(50)    5 (29)     0 (0)   5 (22)    5 (63)   1 (100)   29(36)
  Medication effect         0 (0)    1(50)   2(20)    10 (59)    1(50)   0 (0)     0 (0)    0 (0)     14 (18)
  Deconditioning            0 (0)    0 (0)   0 (0)    0 (0)      0 (0)   12 (52)   2 (25)   0 (0)     14 (18)
  Infections                2 (12)   1(50)   2 (20)   2 (12)     0 (0)   6 (26)    0 (0)    0 (0)     13(16)
  Sequela                   7 (41)   0 (0)   0 (0)    0 (0)      0 (0)   0 (0)     0 (0)    0 (0)     7 (9)
  Other                     0 (0)    0 (0)   1 (10)   0 (0)      1(50)   0 (0)     1 (13)   0 (0)     3(4)

###### 

NIH global severity with or without consideration of confounders

                                               Global severity without confounder, N (%)                                 
  -------------------------------------------- ------------------------------------------- --------- --------- --------- -----------
  **Global severity with confounder, N (%)**                                                                             
    Mild                                       4                                           31        0         0         35 (19)
    Moderate                                   3                                           8         98        0         109 (58)
    Severe                                     1                                           2         0         42        45 (24)
    Total                                      8 (4)                                       41 (22)   98 (52)   42 (22)   189 (100)

[^1]: These authors contributed equally to this manuscript.
